Company: PCRX
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001396814-25-000061
Chunk: 48

Company: Pacira BioSciences, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 48
---
 asset, physical possession of the asset has been transferred, the customer has significant risks and rewards of ownership of the asset and the Company has a present right to payment at that time.

Pacira BioSciences, Inc.  |  Q1 2025 Form 10-Q  |  Page 13

Disaggregated RevenueThe following table represents disaggregated net product sales in the periods presented as follows (in thousands):Three Months EndedMarch 31,20252024Net product sales:   EXPAREL$136,529 $132,430    ZILRETTA23,338 25,839    iovera°5,123 5,030    Bupivacaine liposome injectable suspension2,604 2,525       Total net product sales$167,594 $165,824 

NOTE 5—INVENTORIES

The components of inventories, net are as follows (in thousands):March 31,December 31,20252024Raw materials$45,890 $50,800 Work-in-process32,280 27,384 Finished goods55,584 47,098      Total$133,754 $125,282 

NOTE 6—FIXED ASSETS

Fixed assets, net, summarized by major category, consist of the following (in thousands):March 31,December 31,20252024Machinery and equipment (1)$160,290 $160,643 Leasehold improvements (1)86,663 86,034 Computer equipment and software (1)24,792 23,473 Office furniture and equipment1,952 1,952 Construction in progress (1)30,529 27,996         Total304,226 300,098 Less: accumulated depreciation(139,775)(132,929)        Fixed assets, net$164,451 $167,169 (1) In April 2025, subsequent to the three months ended March 31, 2025, a ZILRETTA fill line at the Company’s manufacturing facility in Swindon, UK, was placed into service, for which approximately $23.1 million was reclassified from construction in progress to machinery and equipment, leasehold improvements and computer equipment and software.For the three months ended March 31, 2025 and 2024, depreciation expense was $6.8 million and